طبيب زمالة المخ والأعصاب | كليفلاند | الولايات المتحدة 🇸🇦 🇺🇸Neurology resident | UH Cleveland Medical Center @cwruneuro @UHhospitals #VascularNeurology
Thrilled and grateful to match into my #1 choice! Vascular Neurology fellowship at UH Cleveland Medical Center 🎉 Can’t wait to continue learning from one of the best in the field @amrsarrajMD. And the rest of the team! #Match2026#VascularNeurology#Stroke
@Soulll_99 فعلاً، موضوع إنك ما تساعد إلا بفلوس صار غريب جدًا. الواحد ينسى بداياته والناس اللي وقفت معه وساعدته بدون مقابل. أشوف إن دعم الزملاء في المرحلة هذي أهم بكثير من استغلال حاجتهم…
من الأخطاء الشائعة اعتقاد أن حركة طرفَي الجسم مع بقاء الوعي أثناء النوبة يعني أن النوبة ليست صرعية. هذا غير صحيح دائمًا، فبعض النوبات الصرعية، خصوصًا الناشئة من الفص الجبهي، قد تظهر بهذه الصورة. لذلك يبقى أخذ التاريخ المرضي بدقة ومشاهدة فيديو للنوبة -إذا أمكن- مهمين للتشخيص
Great summary! Two things worth adding:
1- ABCD2 score > 4 was used as an enrollment criterion in CHANCE and POINT trials which is why score ≥4 became the “high risk TIA” threshold for DAPT. But the score alone shouldn’t be the only thing driving the DAPT decision. A TIA patient with ABCD-2 score <4 with high risk imaging features like large artery stenosis or recurrent pattern carries similar recurrence risk and may still need DAPT.
2- For stroke with NIHSS ≥4 = single antiplatelet cutoff is now outdated. The 2026 AHA/ASA guidelines expanded DAPT eligibility to NIHSS of 5 or less based on THALES & INSPIRES trials which both showed reduced recurrence of stroke at 90 days in pts with presumed atherosclerotic etiology.
For the 2nd consecutive Hajj season operating our Mobile Stroke Unit at the Holy Mosque - one of the world's largest mass gatherings.
Stroke can't wait, so we brought the hospital to the patient.
Rapid diagnosis, faster treatment, lives saved.
A proud Saudi experience! 🧠🇸🇦
.@amrsarrajMD presents ATLAS meta-analysis data demonstrating an "overwhelming benefit" with thrombectomy in large-core ischaemic strokes across six RCTs, with the only potential exception being core volumes ≥150ml presenting beyond six hours
#ESOC2026@ESOstroke
On behalf of the large core trials principal investigators, immensely proud and honored to present primary results of the ATLAS IPD meta-analysis @ESOstroke with simultaneous publication in
@TheLancet -https://t.co/uY3DlB6KPJ
EVT not only improved outcomes compared to medical care, but functional independence and independent ambulation were also achieved in a meaningful proportion of patients. Additionally, EVT was life-saving, as one of the few reperfusion therapies to achieve it. With the exception of patients with very large core (volume ≥150 ml) in the late time window, where evidence is limited because of wide confidence intervals but benefit could not be excluded, EVT demonstrated consistent benefit regardless of ASPECTS and ischaemic core strata.
Our deepest gratitude to the patients, their families, and all investigators and coordinators at the trial sites. A mammoth collective effort over 3 years from 6 trials with practice changing results that improve care for 20% LVOs! #stroke #EVT #largecore #NoLVOleftbehind @XiaochuanHuo@VCostalat@oozaidat@VYogendrakumar@deeppujara@dliebesk@ARazzakMD@NguyenThanhMD@samialkasab@AmeerEHassan@Michael3Abraham@FelixSun1230@HiroshiYamagam2@SunilAShethMD@Fie0815@RaulNogueiraMD@rgrandhi@PascalJabbourMD@shazamhussain@dr_mchen@mihill68@lapergue6@TudorGJovin@AlbertJYoo
ATLAS meta-analysis of 6 trials on EVT for large core infarcts confirms large treatment effect of EVT, reducing disability and mortality, with a NNT of 4,2.
Treatment benefit was consistent over clinical and most imaging subgroups.
@ESOstroke#VoiceOfStroke#Stroke#ESOC2026